Neoadjuvant therapy for gastrointestinal stromal tumors: A propensity score-weighted analysis

Keyphrases

• Adjuvant Imatinib 8%
• Between-group 8%
• Clinical Benefit 8%
• Colorectum 8%
• Covariables 8%
• Cox Proportional Hazards Model 8%
• Duration of Therapy 8%
• Esophagus 8%
• Gastric GIST 8%
• Gastrointestinal Stromal Tumor 100%
• High Risk 8%
• High-risk Features 8%
• Inverse Probability of Treatment Weighting 8%
• Large Tumors 8%
• Low Risk 8%
• Mitotic Index 8%
• National Cancer Database 8%
• Neoadjuvant Systemic Therapy 100%
• Neoadjuvant Therapy 100%
• Overall Survival 8%
• Postoperative Mortality 33%
• Propensity Score 100%
• R0 Resection 16%
• R0 Resection Rate 8%
• Resection 8%
• Risk-benefit 8%
• Small Intestine 8%
• Stomach 8%
• Survival Benefit 16%
• Treatment Group 8%
• Upfront Resection 25%
• Weight Analysis 100%
• Weighted Logistic Regression 8%

Medicine and Dentistry

• Arm 8%
• Esophagus 8%
• Gastrointestinal Stromal Tumor 100%
• Imatinib 8%
• Logistic Regression Analysis 8%
• Malignant Neoplasm 8%
• Mitotic Index 8%
• Mortality Rate 8%
• Neoadjuvant Therapy 100%
• Neoplasm 8%
• Overall Survival 8%
• Proportional Hazards Model 8%
• Prospective Study 8%
• Surgery 58%
• Surgical Mortality 33%
• Systemic Therapy 100%
• Treatment Duration 8%